Prelude Therapeutics Incorporated PRLD
3.23 USD -0.02 (-0.77%)
Regular-session close
3.23 0.00 0.00%
After hours · Nov 20, 4:01 PM ET
3.17 Day range 3.30
1.30 52-week range 6.83
- YTD
- +11.38%
- 1 year
- +101.87%
News
benzinga.com HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $8 price target.
zacks.com Prelude Therapeutics Incorporated (PRLD) Reports Q3 Loss, Beats Revenue Estimates Prelude Therapeutics Incorporated (PRLD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.26 per share a year…benzinga.com Prelude Therapeutics Q3 EPS $(0.12) Misses $0.04 Estimate, Sales $5.647M Miss $29.000M Estimate Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $0.04 by 400 percent. This is a 53.85 percent increase over losses of…
globenewswire.com Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Enrollment of Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer is underway; initial proof of concept data anticipated in the 2 nd half of 2027
